An Italian Multicenter Study for Application of a Diagnostic Algorithm in Autoantibody Testing

被引：14

作者：

Bonaguri, Chiara ^{[1
]}

Melegari, Alessandra ^{[4
]}

Dall'Aglio, PierPaolo ^{[2
]}

Ballabio, Andrea ^{[5
]}

Terenziani, Paolo ^{[6
]}

Russo, Annalisa ^{[1
]}

Battistelli, Luisita ^{[1
]}

Aloe, Rosalia ^{[1
]}

Camisa, Roberta ^{[1
]}

Campaniello, Giovanna ^{[3
]}

Sartori, Elisabetta ^{[3
]}

Monica, Cesare ^{[1
]}

机构：

[1] Parma Hosp, Diagnost Lab Dept, Parma, Italy

[2] Parma Hosp, Dept Immunol, Parma, Italy

[3] Parma Hosp, Dept Adm, Parma, Italy

[4] Modena Hosp, Diagnost Lab Dept, Modena, Italy

[5] Piacenza Hosp, Diagnost Lab Dept, Piacenza, Italy

[6] Reggio Emilia Hosp, Diagnost Lab Dept, Reggio Emilia, Italy

来源：

CONTEMPORARY CHALLENGES IN AUTOIMMUNITY | 2009年 / 1173卷

关键词：

diagnostic algorithm; autoimmune rheumatic disease; antinuclear antibodies; anti-extractable nuclear antigens; anti-double-stranded DNA; AUTOIMMUNE; GUIDELINES; REQUEST;

D O I：

10.1111/j.1749-6632.2009.04635.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The presence in the serum of specific autoantibodies, such as antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), and antiextractable nuclear antigens (anti-ENA), is one of the diagnostic criteria for autoimmune rheumatic disease, and the requests for these tests in the last few years have grown remarkably. A guideline for reducing clinically inappropriate requests in autoantibody testing (ANA, anti-dsDNA, anti-ENA) has been applied in the Parma Hospital since 2007. The results for the period January-December 2007 were compared to those of the previous period January-December 2006, and a significant reduction in the number of anti-dsDNA (23.9%) and anti-ENA (20.7%) was found. The aim of this study was to assess the applicability of a similar guideline in a wide area (Parma, Modena, Piacenza, Reggio-Emilia) with reference to the diagnosis of autoimmune rheumatic disease. This project, supported by a regional grant for innovative research projects, was started in January 2008 and consists of three different steps: (1) a study group of clinicians and laboratory physicians to evaluate the diagnostic criteria, the analytical procedures, and the number of tests performed in different hospitals; (2) developing common guidelines for autoantibody testing that takes into account the different clinical needs with the aim of improving efficiency and clinical effectiveness of diagnosis and monitoring; and (3) assessing compliance with the guidelines in the different hospitals that are evaluating the second-level test (anti-dsDNA, anti-ENA) decrease. We think that the validation of guidelines for the laboratory diagnosis of autoimmune rheumatic disease can represent a tool for improving patients' outcomes and economic efficiency.

引用

页码：124 / 129

页数：6

共 16 条

[1]

Bizzaro N, 2004, CLIN EXP RHEUMATOL, V22, P349

[2] Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].